AN2 Therapeutics Inc. (ANTX)
1.26
-0.05 (-3.82%)
At close: Apr 15, 2025, 3:59 PM
1.28
1.48%
Pre-market: Apr 16, 2025, 05:06 AM EDT
-3.82% (1D)
| Bid | 1.24 |
| Market Cap | 37.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -51.32M |
| EPS (ttm) | -1.76 |
| PE Ratio (ttm) | -0.72 |
| Forward PE | -1.03 |
| Analyst | Hold |
| Ask | 1.39 |
| Volume | 17,029 |
| Avg. Volume (20D) | 123,686 |
| Open | 1.32 |
| Previous Close | 1.31 |
| Day's Range | 1.26 - 1.32 |
| 52-Week Range | 0.87 - 3.07 |
| Beta | -0.01 |
About ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California....
Industry Biotechnology
Sector Healthcare
IPO Date Mar 25, 2022
Employees 22
Stock Exchange NASDAQ
Ticker Symbol ANTX
Website https://www.an2therapeutics.com
Analyst Forecast
According to 5 analyst ratings, the average rating for ANTX stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 296.83% from the latest price.
Stock Forecasts8 months ago
-60.98%
AN2 Therapeutics shares are trading lower after th...
Unlock content with
Pro Subscription
8 months ago
+6.88%
AN2 Therapeutics shares are trading lower after the company announced that it will discontinue its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.
